| 2008-03-05 | Earnings/Dividends | ExonHit Therapeutics S.A., a French drug and diagnostic discovery company, today announces its consolidated financial results for the year ending December 31, 2007.
2007 Key Events
Milestone reached in the therapeutic research collaboration with Allergan Inc., in view of the initiation of Phase 1 trials with the first compound resulting from the collaboration;
Approval by the AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante) and by ethics committees to initiate a clinical trial on 135 patients suffering from Alzheimer's disease, as a result of Phase 1 clinical trials of EHT0202 which were successfully realized during the year;
Prototype of the first blood test of Alzheimer's Disease which the Company wishes to sell, as a first commercial step and as early as 2009, in its service laboratories which are GLPS (Good Laboratory Practices Standards) compliant, to the pharmaceutical industry;
Signature of an amendment to the strategic partnership with bioMerieux in the field of cancer diagnostics. Pursuant to this amendment, ExonHit obtained certain commercial rights to diagnostic tools resulting from the collaboration and bioMerieux will have more flexibility to initiate new R&D programs in this field;
New genomic map for the analysis of the murine genome;
Increased financial resources, substantial improvement of stock liquidity and higher free float.
Other 2007 important events
Key financial figures
Total revenues at EUR 5.4 million in 2007 (EUR 5.6 million in 2006);
R&D expenses at EUR 8.6 million in 2007 (EUR 6.8 million in 2006);
Operating loss at EUR 7.8 million in 2007 (EUR 5.0 million in 2006);
Net loss of EUR 7.3 million, against EUR 4.5 million in 2006; Cash burn from operations remained limited at EUR 4.9 million (EUR 3.9 million in 2006);
Consolidated cash and cash equivalents position increased to EUR 31.3 million at December 31, 2007 by issuance of new shares against EUR 24.0 million at December 31, 2006.
Strategic progress in therapeutics
New financial commitments from Allergan on the collaboration with the nomination in regulatory pre development of a second compound resulting from the collaboration.
Strengthened position in diagnostics
Initiation of a new program in the field of blood diagnostic of prostate cancers in the framework of the collaboration signed with bioMerieux. To this end, ExonHit has initiated to the financing of clinical trials in Austria to speed the collection of blood samples.
Development of the SpliceArray(TM) business
Implementation and certification of an Affymetrix platform to equip a second service laboratory in Paris.
Strengthened patent portfolio
10 new patents were filed in 2007, bringing the total of active patents filed since the Company's creation in 1997 to 177. 26 patents have been granted to ExonHit Therapeutics since its inception.
Bruno Tocque, President of the Management Board of ExonHit, commented: "We have reached our main objectives in 2007. We are very proud of the work accomplished by our collaborators in a context of market agitation which has been very disturbing for companies like ExonHit which invest in innovation with 65% of its operating expenses devoted to R&D.
We have kept our cash burn from operations below EUR 5 million while still investing more in R&D than in 2006. At December 31, 2007, we have an enviable cash and cash equivalent position of EUR 31.3 million. We will thereby have the capacity to continue our investment efforts, and notably in Alzheimer's disease to market our first blood diagnostic for the detection of AD and to continue our clinical research program with our compound EHT0202.
I am very confident in the efforts of our teams to obtain GBEA accreditation of our two GLPS service laboratories in molecular biology, both in Paris and in Gaithersburg, to serve biomedical research and our own medical diagnostics in |
| 2008-01-25 | Alliances | Allergan, Inc. (NYSE:AGN) and Clinique Laboratories, LLC, today announced a strategic collaboration which combines Clinique’s expertise in product development and formulation with Allergan’s leadership in the medical aesthetics market. The new skin care line, which will incorporate the Clinique brand name, will offer clinically proven skin care products to complement in-office aesthetic procedures. It will be sold exclusively in physicians’ offices in the United States and is expected to launch in the fall of 2008. |
| 2008-01-25 | Alliances | Allergan, Inc. (NYSE:AGN) and Clinique Laboratories, LLC, today announced a strategic collaboration which combines Clinique’s expertise in product development and formulation with Allergan’s leadership in the medical aesthetics market. The new skin care line, which will incorporate the Clinique brand name, will offer clinically proven skin care products to complement in-office aesthetic procedures. It will be sold exclusively in physicians’ offices in the United States and is expected to launch in the fall of 2008. |
| 2008-01-24 | Contract/Agreements | IRVINE, Calif. & NEW YORK--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) and Clinique Laboratories, LLC, today announced a strategic collaboration which combines Cliniques expertise in product development and formulation with Allergans leadership in the medical aesthetics market. The new skin care line, which will incorporate the Clinique brand name, will offer clinically proven skin care products to complement in-office aesthetic procedures. It will be sold exclusively in physicians offices in the United States and is expected to launch in the fall of 2008.
Over the past ten years, non-surgical aesthetic procedures have increased nearly 750 percent, with consumers in the United States spending more than $12 billion on cosmetic procedures in 20061. The top five non-surgical aesthetic treatments in 2006, administered in the physicians office, included BOTOX Cosmetic and hyaluronic acid dermal fillers such as JUVDERM, laser hair removal, microdermabrasion and laser skin resurfacing. As more patients seek advice and treatments from aesthetic specialty physicians, there is a similar, growing trend of consumers purchasing skin care products in the physicians office. Allergan and Clinique expect to pioneer a new category of best-in-class skin care products sold exclusively in physicians offices that will be Allergy Tested and 100% Fragrance Free.
In collaboration with Clinique, our goal is to establish a leadership position in physician-dispensed skin care by offering a one-stop approach to specialized skin care products under a brand name that is trusted by consumers and backed by science on which physicians can rely, said David E.I. Pyott, Allergans Chairman of the Board and Chief Executive Officer. The collaboration combines Allergans leadership in medical aesthetics and our deep understanding of the physician channel based on our Total Facial Rejuvenation portfolio including BOTOX Cosmetic, JUVDERM and our skin care product line, with Cliniques history of formulating leading consumer skin care products guided by dermatologists. Together with our complementary strengths, we expect Clinique and Allergan to grow this market.
Cliniques promise to our consumers has always been to create dermatologist guided, Allergy Tested, 100% Fragrance Free products that address skin care needs. Today we are entering a new phase of our relationship with the medical community, said Lynne Greene, Global President, Clinique Laboratories. By joining forces with Allergan, the number one medical aesthetics company, we are now able to service consumers who are under the care of a physician with this completely new class of products.
Cliniques rich dermatological heritage dates back 40 years, said William P. Lauder, President and Chief Executive Officer, The Este Lauder Companies Inc. This new skin care line, created in collaboration with Allergan, is the next generation of the expression of Cliniques unique position delivered through one of the fastest growing channels today, physicians offices.
As part of the agreement, Clinique will be responsible for formulating, developing and manufacturing the new product line. Clinique will sell products to Allergan while Allergan will record sales to physicians and handle consumer and professional marketing and distribution. The agreement with Clinique will allow Allergan to expand the size of its current sales force dedicated to physician-dispensed skin care. Clinique and Allergan may also conduct clinical trials and work with the physician community to ensure the success of the new skin care line.
Important BOTOX Cosmetic (Botulinum Toxin Type A) Information
BOTOX Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe frown lines between the brows in people 18 to 65 years of age.
Important BOTOX Cosmetic (Botulinum Toxin Type A) Safety Information
Serious heart problems and serious allergic reactions have been reported rarely. If you think you |
| 2008-01-17 | Alliances | Affiliated Computer Services, Inc. announced today that it has been awarded a seven-year, $130 million contract to provide information technology outsourcing (ITO) services for Allergan, Inc. , a premier, global multi-specialty healthcare company.
Under the terms of the contract, ACS will supply comprehensive infrastructure services, including data center operations, network monitoring and management, and end-user support services. The ACS-designed solution will provide the scale necessary to meet Allergan's growth, as well as access to new technology to support its unique industry needs.
"This key relationship further expands our presence in the pharmaceutical industry and allows us to develop and strengthen our industry-specific competencies," said Ann Vezina, group president of ACS Commercial Solutions. "Our partnership will enable Allergan to focus on its global core business operations as the company grows and help meet Allergan's need for advanced technological capabilities."
Along with comprehensive ITO services, ACS will implement an innovative platform that utilizes a network connection to store important data online, provide additional data security, and more reliably restore backup data. The solution replicates backup data directly to the disaster recovery site, thereby reducing business recovery time and incidence of data loss by eliminating off-site data handling.
Sue-Jean Lin, Allergan's Chief Information Officer, said, "With our many innovative products, we operate in a wide range of global, high-growth markets. We needed a strategic partner who could not only support our market-leading positions, but help us meet the challenges of continued expansion. ACS has the technology and expertise to meet our growth needs, and their dedication to quality service makes them a strong cultural fit as well."
Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential -- to see more clearly, move more freely, express themselves more fully. The Company employs more than 7,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries. |
| 2008-01-16 | Contract/Agreements | Affiliated Computer Services, Inc. announced today that it has been awarded a seven year, $130 million contract to provide information technology outsourcing (ITO) services for Allergan, Inc. (NYSE: AGN), a premier, global multi specialty healthcare company.
Under the terms of the contract, ACS will supply comprehensive infrastructure services, including data center operations, network monitoring and management, and end user support services. The ACS designed solution will provide the scale necessary to meet Allergan's growth, as well as access to new technology to support its unique industry needs.
"This key relationship further expands our presence in the pharmaceutical industry and allows us to develop and strengthen our industry specific competencies," said Ann Vezina, group president of ACS Commercial Solutions. "Our partnership will enable Allergan to focus on its global core business operations as the company grows and help meet Allergan's need for advanced technological capabilities."
Along with comprehensive ITO services, ACS will implement an innovative platform that utilizes a network connection to store important data online, provide additional data security, and more reliably restore backup data. The solution replicates backup data directly to the disaster recovery site, thereby reducing business recovery time and incidence of data loss by eliminating off site data handling.
Sue Jean Lin, Allergan's Chief Information Officer, said, "With our many innovative products, we operate in a wide range of global, high growth markets. We needed a strategic partner who could not only support our market leading positions, but help us meet the challenges of continued expansion. ACS has the technology and expertise to meet our growth needs, and their dedication to quality service makes them a strong cultural fit as well."
Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential to see more clearly, move more freely, express themselves more fully. The Company employs more than 7,500 people worldwide and operates state of the art R&D facilities and world class manufacturing plants. In addition to its discovery to development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.
ACS, a global FORTUNE 500 company with 62,000 people supporting client operations reaching more than 100 countries, provides business process outsourcing and information technology solutions to world class commercial and government clients. The company's Class A common stock trades on the New York Stock Exchange under the symbol "ACS." Visit ACS on the Internet at http://www.acs inc.com.
The statements in this news release that do not directly relate to historical facts constitute "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to numerous risks and uncertainties, many of which are outside the Company's control. As such, no assurance can be given that the actual events and results will not be materially different than the anticipated results described in the forward looking statements. Factors could cause actual results to differ materially from such forward looking statements. For a description of these factors, see the company's prior filings with the Securities and Exchange Commission, including our most recent filing. ACS disclaims any intention or obligation to revise any forward looking statements, whether as a result of new information, future event, or otherwise. s.server=server() s.channel="news release" s.pageName="news_release_acs awarded $130 million contract to provide it outsourcing services to allergan, inc." s.prop2="109" s.prop3="01 16 2008" |